ROTH Capital Partners Acts as Sole Placement Agent for
Roka Bioscience, Inc. (ROKA) in its $22.5 Million PIPE

For more information please contact:

Investment Banking
John Chambers
Vice-Chairman and
Head of Healthcare
Investment Banking

(646) 358-1901

Michael Margolis, R.Ph
Managing Director
(646) 358-1902


Christopher (Kit) Jennings
Managing Director
(310) 445-5865


Adam Stormoen
(612) 720-8136

Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703


Nazan Akdeniz
Senior Vice President
(949) 720-5740


Lou Ellis
Senior Vice President
(949) 720-5739

Transaction Information

Roka Bioscience, Inc. (ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, has completed a securities purchase agreement in connection with a private placement. Roka will receive gross proceeds of approximately $22.5 million resulting from the sale of approximately 22,500 shares of the Company's Series A Preferred Stock. Each share of Series A Preferred Stock is convertible into approximately 1,428 shares of the Company's common stock, which is equivalent to a purchase price of $0.70 per common share, or an aggregate of approximately 32,143,000, subject to customary adjustments and certain issuance limitations. The purchasers will receive a five-year warrant to purchase approximately 1,428 shares of the Company's common stock, or an aggregate of approximately 32,143,000, at an exercise price of $0.70 per share for each share of Series A Preferred Stock purchased. Roka plans to use the proceeds for general corporate purposes.


ROTH Capital Partners acted as Sole Placement Agent in the transaction.


About Roka Bioscience, Inc.
Roka Bioscience, Inc. is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas® Detection Assays incorporate our advanced molecular technologies and are performed on our "sample-in, result out" Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies. For more information, visit (Source: Company Press Release | 9/16/16)


About ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S.  For more information on ROTH, please visit

About ROTH Investment Banking Venture Finance Institutional Sales & Trading
Research Corporate Services Marketing & Conferences Press Room

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2016.